











DataViz Final Project Report

| Subtopic | Figure | Source |
|----------------|---|---|
| General | | |
| |  | https://en.wikipedia.org/wiki/Legality_of_cannabis |
| |  | https://www.worldatlas.com/articles/countries-that-have-decriminalized-drugs.html |
| |  | https://www.unodc.org/unodc/en/data-and-analysis/wdr2021_annex.html |
| |  | https://www.unodc.org/unodc/en/data-and-analysis/wdr2021_annex.html |
| |  | https://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-events/deaths/drug-related-deaths-in-scotland/2020 https://www.emcdda.europa.eu/data/stats2022/drd_en https://ind.obsan.admin.ch/en/indicator/monam/drug-related-deaths |
| Health | | |

| <p>Adults supporting use of opioids for cancer patients</p> | <p>Percentage of adults supporting use of opioids for cancer patients in 2019, US</p> <table border="1"> <thead> <tr> <th>Type of cancer experience</th> <th>Percentage</th> </tr> </thead> <tbody> <tr> <td>Have/had cancer</td> <td>74%</td> </tr> <tr> <td>Family member/loved one has cancer</td> <td>75%</td> </tr> <tr> <td>Caregiver</td> <td>74%</td> </tr> <tr> <td>No cancer experience</td> <td>68%</td> </tr> <tr> <td>Average</td> <td>70%</td> </tr> </tbody> </table> | Type of cancer experience | Percentage | Have/had cancer | 74% | Family member/loved one has cancer | 75% | Caregiver | 74% | No cancer experience | 68% | Average | 70% | <p>https://www.statista.com/statistics/944423/prescription-opioid-use-for-cancer-treatment-opinions-us-by-cancer-experience/</p> | | | | | | | | | | |
|---|---|---------------------------|-----------------|--------------------|----------------------|------------------------------------|--------|---------------------------------|--------|----------------------|--|---------|-------|--|-------|----------------------|--|--------------|-------|-------------|-------|------------|-------|--|
| Type of cancer experience | Percentage | | | | | | | | | | | | | | | | | | | | | | | |
| Have/had cancer | 74% | | | | | | | | | | | | | | | | | | | | | | | |
| Family member/loved one has cancer | 75% | | | | | | | | | | | | | | | | | | | | | | | |
| Caregiver | 74% | | | | | | | | | | | | | | | | | | | | | | | |
| No cancer experience | 68% | | | | | | | | | | | | | | | | | | | | | | | |
| Average | 70% | | | | | | | | | | | | | | | | | | | | | | | |
| <p>Drug-related visits to the ED 2021</p> | <p>Drug-related visits to the Emergency Department in Nov 2021, USA</p> <table border="1"> <thead> <tr> <th>Drug Category</th> <th>Percentage</th> </tr> </thead> <tbody> <tr> <td>Alcohol</td> <td>50.75%</td> </tr> <tr> <td>Methamphetamine</td> <td>16.39%</td> </tr> <tr> <td>Marijuana</td> <td>10.51%</td> </tr> <tr> <td>Cocaine</td> <td>8.48%</td> </tr> <tr> <td>Heroin</td> <td>4.74%</td> </tr> <tr> <td>Fentanyl</td> <td>5.32%</td> </tr> <tr> <td>Narcotics analgesics</td> <td>3.55%</td> </tr> <tr> <td>Drug unknown</td> <td>3.77%</td> </tr> <tr> <td>Amphetamine</td> <td>1.50%</td> </tr> <tr> <td>Alprazolam</td> <td>1.29%</td> </tr> </tbody> </table> | Drug Category | Percentage | Alcohol | 50.75% | Methamphetamine | 16.39% | Marijuana | 10.51% | Cocaine | 8.48% | Heroin | 4.74% | Fentanyl | 5.32% | Narcotics analgesics | 3.55% | Drug unknown | 3.77% | Amphetamine | 1.50% | Alprazolam | 1.29% | <p>https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP22-07-03-001.pdf</p> |
| Drug Category | Percentage | | | | | | | | | | | | | | | | | | | | | | | |
| Alcohol | 50.75% | | | | | | | | | | | | | | | | | | | | | | | |
| Methamphetamine | 16.39% | | | | | | | | | | | | | | | | | | | | | | | |
| Marijuana | 10.51% | | | | | | | | | | | | | | | | | | | | | | | |
| Cocaine | 8.48% | | | | | | | | | | | | | | | | | | | | | | | |
| Heroin | 4.74% | | | | | | | | | | | | | | | | | | | | | | | |
| Fentanyl | 5.32% | | | | | | | | | | | | | | | | | | | | | | | |
| Narcotics analgesics | 3.55% | | | | | | | | | | | | | | | | | | | | | | | |
| Drug unknown | 3.77% | | | | | | | | | | | | | | | | | | | | | | | |
| Amphetamine | 1.50% | | | | | | | | | | | | | | | | | | | | | | | |
| Alprazolam | 1.29% | | | | | | | | | | | | | | | | | | | | | | | |
| <p>Comparison of medical and illicit use of medications</p> | <table border="1"> <thead> <tr> <th>Medication Type</th> <th>Medical use (%)</th> <th>Illicit use (%)</th> </tr> </thead> <tbody> <tr> <td>Sleeping medications</td> <td>3.3</td> <td>2.0</td> </tr> <tr> <td>Sedative or anxiety medications</td> <td>3.4</td> <td>2.9</td> </tr> <tr> <td>Stimulant medication for ADHD</td> <td>2.2</td> <td>5.4</td> </tr> <tr> <td>Pain medication</td> <td>24.4</td> <td>9.3</td> </tr> </tbody> </table> | Medication Type | Medical use (%) | Illicit use (%) | Sleeping medications | 3.3 | 2.0 | Sedative or anxiety medications | 3.4 | 2.9 | Stimulant medication for ADHD | 2.2 | 5.4 | Pain medication | 24.4 | 9.3 | <p>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1876754/</p> | | | | | | | |
| Medication Type | Medical use (%) | Illicit use (%) | | | | | | | | | | | | | | | | | | | | | | |
| Sleeping medications | 3.3 | 2.0 | | | | | | | | | | | | | | | | | | | | | | |
| Sedative or anxiety medications | 3.4 | 2.9 | | | | | | | | | | | | | | | | | | | | | | |
| Stimulant medication for ADHD | 2.2 | 5.4 | | | | | | | | | | | | | | | | | | | | | | |
| Pain medication | 24.4 | 9.3 | | | | | | | | | | | | | | | | | | | | | | |
| <p>Microdosing</p> | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>Microdosers/Non-microdosers Anxiety</p> | <p>Microdosing and mental health</p> <table border="1"> <thead> <tr> <th>Group</th> <th>Percentage</th> <th>Mean DASS-21 score</th> </tr> </thead> <tbody> <tr> <td>Microdosed</td> <td>46.82%</td> <td>11.44</td> </tr> <tr> <td>Non-microdosed</td> <td>53.18%</td> <td>12.23</td> </tr> </tbody> </table> | Group | Percentage | Mean DASS-21 score | Microdosed | 46.82% | 11.44 | Non-microdosed | 53.18% | 12.23 | <p>https://www.nature.com/articles/s41598-021-01811-4#data-availability</p> | | | | | | | | | | | | | |
| Group | Percentage | Mean DASS-21 score | | | | | | | | | | | | | | | | | | | | | | |
| Microdosed | 46.82% | 11.44 | | | | | | | | | | | | | | | | | | | | | | |
| Non-microdosed | 53.18% | 12.23 | | | | | | | | | | | | | | | | | | | | | | |



| <p>Depression</p> | <p>Microdosing and mental health</p> <table border="1"> <caption>Mean DASS-21 score for Depression</caption> <thead> <tr> <th>Group</th> <th>Percentage</th> <th>Mean DASS-21 score</th> </tr> </thead> <tbody> <tr> <td>Microdosed</td> <td>47.12%</td> <td>18.34</td> </tr> <tr> <td>Non-microdosed</td> <td>52.88%</td> <td>20.98</td> </tr> </tbody> </table> | Group | Percentage | Mean DASS-21 score | Microdosed | 47.12% | 18.34 | Non-microdosed | 52.88% | 20.98 | <p>https://www.nature.com/articles/s41598-021-01811-4#data-availability</p> | | | | | | | | | | | | | | | |
|----------------------------|---|--------------------|------------|--------------------|------------|---------------------------|-------|-----------------|--------|-----------------|--|--------------------------|-------|-----------------|------|----------------------------|-------|--------------------|------|--------------------------|------|--------------------------|------|--------------------|------|--|
| Group | Percentage | Mean DASS-21 score | | | | | | | | | | | | | | | | | | | | | | | | |
| Microdosed | 47.12% | 18.34 | | | | | | | | | | | | | | | | | | | | | | | | |
| Non-microdosed | 52.88% | 20.98 | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>Stress</p> | <p>Microdosing and mental health</p> <table border="1"> <caption>Mean DASS-21 score for Stress</caption> <thead> <tr> <th>Group</th> <th>Percentage</th> <th>Mean DASS-21 score</th> </tr> </thead> <tbody> <tr> <td>Microdosed</td> <td>48.54%</td> <td>19.90</td> </tr> <tr> <td>Non-microdosed</td> <td>51.46%</td> <td>21.10</td> </tr> </tbody> </table> | Group | Percentage | Mean DASS-21 score | Microdosed | 48.54% | 19.90 | Non-microdosed | 51.46% | 21.10 | <p>https://www.nature.com/articles/s41598-021-01811-4#data-availability</p> | | | | | | | | | | | | | | | |
| Group | Percentage | Mean DASS-21 score | | | | | | | | | | | | | | | | | | | | | | | | |
| Microdosed | 48.54% | 19.90 | | | | | | | | | | | | | | | | | | | | | | | | |
| Non-microdosed | 51.46% | 21.10 | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>Benefits</p> | <p>Benefits of microdosing</p> <table border="1"> <caption>Benefits of microdosing (N = 807)</caption> <thead> <tr> <th>Benefit</th> <th>Percentage</th> </tr> </thead> <tbody> <tr><td>Improved Mood</td><td>26.6%</td></tr> <tr><td>Self-Efficacy</td><td>11.3%</td></tr> <tr><td>Improved Energy</td><td>10.5%</td></tr> <tr><td>Improved Focus</td><td>14.8%</td></tr> <tr><td>Social Benefits</td><td>7.6%</td></tr> <tr><td>Reduced Anxiety</td><td>6.2%</td></tr> <tr><td>Creativity</td><td>12.9%</td></tr> <tr><td>Cognitive Benefits</td><td>5.8%</td></tr> <tr><td>Other Perceived Benefits</td><td>2.2%</td></tr> <tr><td>Physiological Discomfort</td><td>1.1%</td></tr> <tr><td>Reduced Symptoms</td><td>1.1%</td></tr> </tbody> </table> | Benefit | Percentage | Improved Mood | 26.6% | Self-Efficacy | 11.3% | Improved Energy | 10.5% | Improved Focus | 14.8% | Social Benefits | 7.6% | Reduced Anxiety | 6.2% | Creativity | 12.9% | Cognitive Benefits | 5.8% | Other Perceived Benefits | 2.2% | Physiological Discomfort | 1.1% | Reduced Symptoms | 1.1% | <p>https://osf.io/g5cwy/</p> |
| Benefit | Percentage | | | | | | | | | | | | | | | | | | | | | | | | | |
| Improved Mood | 26.6% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Self-Efficacy | 11.3% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Improved Energy | 10.5% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Improved Focus | 14.8% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Social Benefits | 7.6% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Reduced Anxiety | 6.2% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Creativity | 12.9% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Cognitive Benefits | 5.8% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Other Perceived Benefits | 2.2% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Physiological Discomfort | 1.1% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Reduced Symptoms | 1.1% | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>Challenges</p> | <p>Challenges of microdosing</p> <table border="1"> <caption>Challenges of microdosing (N = 603)</caption> <thead> <tr> <th>Challenge</th> <th>Percentage</th> </tr> </thead> <tbody> <tr><td>Illegality</td><td>29.5%</td></tr> <tr><td>Other Perceived Drawbacks</td><td>16.6%</td></tr> <tr><td>Impaired Focus</td><td>8.8%</td></tr> <tr><td>Impaired Energy</td><td>7.3%</td></tr> <tr><td>Physiological Discomfort</td><td>18.6%</td></tr> <tr><td>Impaired Mood</td><td>6.9%</td></tr> <tr><td>Increased Symptoms (Other)</td><td>6.2%</td></tr> <tr><td>Increased Anxiety</td><td>6.7%</td></tr> <tr><td>Social Isolation</td><td>2.6%</td></tr> <tr><td>Cognitive Interference</td><td>2.5%</td></tr> <tr><td>Self-Interferences</td><td>1.2%</td></tr> </tbody> </table> | Challenge | Percentage | Illegality | 29.5% | Other Perceived Drawbacks | 16.6% | Impaired Focus | 8.8% | Impaired Energy | 7.3% | Physiological Discomfort | 18.6% | Impaired Mood | 6.9% | Increased Symptoms (Other) | 6.2% | Increased Anxiety | 6.7% | Social Isolation | 2.6% | Cognitive Interference | 2.5% | Self-Interferences | 1.2% | <p>https://osf.io/g5cwy/</p> |
| Challenge | Percentage | | | | | | | | | | | | | | | | | | | | | | | | | |
| Illegality | 29.5% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Other Perceived Drawbacks | 16.6% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Impaired Focus | 8.8% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Impaired Energy | 7.3% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Physiological Discomfort | 18.6% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Impaired Mood | 6.9% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Increased Symptoms (Other) | 6.2% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Increased Anxiety | 6.7% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Social Isolation | 2.6% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Cognitive Interference | 2.5% | | | | | | | | | | | | | | | | | | | | | | | | | |
| Self-Interferences | 1.2% | | | | | | | | | | | | | | | | | | | | | | | | | |

| | | |
|--|---|--|
| <p>Overall harm score</p> |  <p>Overall harm score</p> <p>Legend: Alcohol, Heroin, Crack, Tobacco, Ecstasy, LSD, Methuons</p> | <p>https://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.690.1283</p> |
| <p>Abuse</p> | | |
| <p>Receiving Treatment For Illicit Drug Use With Vs Without Health Insurance</p> |  <p>Receiving Treatment For Illicit Drug Use With Different Types of Health Insurance (In USA, ages 12+)</p> | <p>//Table 5.34 A</p> <p>https://www.samhsa.gov/data/sites/default/files/reports/rpt29394/NSDUHDetailedTabs2019/NSDUHDetailedTabsSect5pe2019.htm</p> |
| <p>Citizens that received Substance Use Treatment</p> |  <p>USA Citizens That Received Substance Use Treatment</p> | <p>//Table 5.19A</p> <p>https://www.samhsa.gov/data/sites/default/files/reports/rpt29394/NSDUHDetailedTabs2019/NSDUHDetailedTabsSect5pe2019.htm</p> |
| <p>Population With Disorder Vs Received Treatment</p> |  <p>Substance Use Disorder Vs Received Treatment (In USA, ages 12+)</p> | <p>//Table 5.1A & Table 5.14A</p> <p>https://www.samhsa.gov/data/sites/default/files/reports/rpt29394/NSDUHDetailedTabs2019/NSDUHDetailedTabsSect5pe2019.htm</p> |
| <p>Crime</p> | | |
| |  | <p>https://dataunodc.un.org/data/drugs/Annual%20Drug%20Seizures</p> |

| | | <p>https://dataunodc.un.org/data/drugs/Annual%20Drug%20Seizures</p> | | | | | | | | | | | | |
|-------------------------|--|--|-----------|-------------|---------|------|----------|--|-----|------|-----|-----|------|--|
| | | <p>https://www150.statcan.gc.ca/n1/pub/85-002-x/2020001/article/00010/tbl/tbl03-eng.htm</p> | | | | | | | | | | | | |
| <p>Economics</p> | | | | | | | | | | | | | | |
| | <p style="text-align: center;">US State and Federal Prison Population 2017</p> <p style="text-align: right;">● = 7000 people</p> <p>People in Prisons & Jails for Drug Offenses</p> <table border="1"> <caption>People in Prisons & Jails for Drug Offenses</caption> <thead> <tr> <th>Year</th> <th>Amount</th> </tr> </thead> <tbody> <tr> <td>1990</td> <td>~40,000</td> </tr> <tr> <td>2015</td> <td>~450,000</td> </tr> </tbody> </table> | Year | Amount | 1990 | ~40,000 | 2015 | ~450,000 | <p>https://www.sentencingproject.org/criminal-justice-facts/</p> | | | | | | |
| Year | Amount | | | | | | | | | | | | | |
| 1990 | ~40,000 | | | | | | | | | | | | | |
| 2015 | ~450,000 | | | | | | | | | | | | | |
| | <p style="text-align: center;">People in US State and Federal Prison</p> <table border="1"> <caption>People in US State and Federal Prison by Drug Type</caption> <thead> <tr> <th>Year</th> <th>Marijuana</th> <th>Other drugs</th> <th>Rest</th> </tr> </thead> <tbody> <tr> <td>1980</td> <td>0%</td> <td>4%</td> <td>96%</td> </tr> <tr> <td>2019</td> <td>11%</td> <td>~8%</td> <td>~81%</td> </tr> </tbody> </table> | Year | Marijuana | Other drugs | Rest | 1980 | 0% | 4% | 96% | 2019 | 11% | ~8% | ~81% | <p>https://www.aclu.org/report/report-war-marijuana-black-and-white</p> |
| Year | Marijuana | Other drugs | Rest | | | | | | | | | | | |
| 1980 | 0% | 4% | 96% | | | | | | | | | | | |
| 2019 | 11% | ~8% | ~81% | | | | | | | | | | | |

Lucas van Koppen | s2330229
Geert Mol | s2382784
Thorben Gerdes | s2302918
Theo Syriopoulos | s2240718
Sade Yokubova | s2425823
Victoria Manchuk | s2424169

20 June, 2022

| | | |
|--|--|--|
| |  <p>A map of the United States showing the status of marijuana legislation by state in 2022. States are color-coded: dark blue for states with full legalization, light blue for states with medical marijuana, and green for states with no legislation. The map includes a legend and a search bar.</p> | <p>https://mjbizdaily.com/map-of-us-marijuana-legalization-by-state/</p> |
| |  <p>A gauge chart titled "US Tax Income from Marijuana 2021". The gauge shows a needle pointing to approximately 3.6 billion dollars. The scale ranges from 0 to 4 billion in increments of 0.4 billion. The needle is orange and the gauge face is blue.</p> | <p>https://www.mpp.org/issues/legalization/cannabis-tax-revenue-states-regulate-cannabis-adult-use/</p> |
| <p>Facts about costs and income from legalising marijunana</p> | | <p>https://www.americanprogress.org/article/ending-war-drugs-numbers/</p> |